Benefit of including CT urography in [68Ga]PSMA-11 PET/CT with low-dose CT: first results from a larger prostate cancer cohort analysis

被引:2
作者
Rosar, Florian [1 ]
Huegle, Martin J. [1 ]
Ries, Martin [1 ]
Bartholomae, Mark [1 ]
Maus, Stephan [1 ]
Fries, Peter [2 ]
Khreish, Fadi [1 ]
Ezziddin, Samer [1 ]
机构
[1] Saarland Univ, Dept Nucl Med, Med Ctr, Kirrbergerstr 100, D-66421 Homburg, Germany
[2] Saarland Univ, Clin Diagnost & Intervent Radiol, Med Ctr, Homburg, Germany
关键词
Glu-NH-CO-NH-Lys-(Ahx)-((68)Ga(HBED-CC); Contrast media; Renal elimination; MEMBRANE ANTIGEN; BIOCHEMICAL RECURRENCE; RADIATION-DOSIMETRY; PSMA; THERAPY; BIODISTRIBUTION; TOMOGRAPHY; STRATEGIES; DIAGNOSIS; TARGET;
D O I
10.23736/S1824-4785.20.03224-0
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
BACKGROUND: Accuracy of [68Ga]PSMA-11 PET/CT may be hampered by ureter accumulation, mimicking lymph node metastases depend-ing on localization and configuration. The benefit of CT urography for differentiation of lymph node metastasis from urinary tract activity was evaluated in a "PET/CT with low-dose CT" setting.METHODS: Retrospective analysis of PET/CT for primary staging, biochemical recurrence or local treatment planning in patients with prostate cancer. For CT urography (CTU), iodinated contrast agent was administered 10 minutes prior to image acquisition. All potential pathologic (peri) ureteral tracer uptake was assigned to excretory ureteral accumulation or pathological lesion. To assess additional provided benefit of CTU all foci were rated with an introduced scoring system (ranging from 0 pts: CTU not needed; up to 3 pts: no differentiation possible without CTU). Success of ureter contrasting was assessed by measurement of Hounsfield units. Besides benefit for reading urography-enhanced PET/CT, the possible impact on subsequent patient treatment was evaluated. RESULTS: A number of N.=247 patients were included in this study. By CT urography, it was possible to identify each ureter on low-dose CT, with its major part contrasted. In 120/247 (48.6%) patients, urography increased the diagnostic confidence while providing substantial support for interpretation in 60 (24.3%) cases. In 42 (17.0%) patients, urography was clinically relevant (up-/downstaging) with potential impact on subsequent patient care. In 30 of these 42 cases (12.1% of all), discrepant treatment would have resulted from a misdiagnosed tracer accumula-tion without urography.CONCLUSIONS: CT urography benefits the interpretation of [68Ga]-PSMA-11 PET/CT with low-dose CT and leads to discrepant patient treat-ment in a small but significant subset of patients (12% in our cohort). The implementation of CT urography into standard protocols of [68Ga] PSMA-11 PET/CT with low-dose CT is recommended.
引用
收藏
页码:280 / 289
页数:10
相关论文
共 46 条
[1]   PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions [J].
Afshar-Oromieh, A. ;
Malcher, A. ;
Eder, M. ;
Eisenhut, M. ;
Linhart, H. G. ;
Hadaschik, B. A. ;
Holland-Letz, T. ;
Giesel, F. L. ;
Kratochwil, C. ;
Haufe, S. ;
Haberkorn, U. ;
Zechmann, C. M. .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 (04) :486-495
[2]   Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients [J].
Afshar-Oromieh, Ali ;
Holland-Letz, Tim ;
Giesel, Frederik L. ;
Kratochwil, Clemens ;
Mier, Walter ;
Haufe, Sabine ;
Debus, Nils ;
Eder, Matthias ;
Eisenhut, Michael ;
Schaefer, Martin ;
Neels, Oliver ;
Hohenfellner, Markus ;
Kopka, Klaus ;
Kauczor, Hans-Ulrich ;
Debus, Juergen ;
Haberkorn, Uwe .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (08) :1258-1268
[3]   The Rise of PSMA Ligands for Diagnosis and Therapy of Prostate Cancer [J].
Afshar-Oromieh, Ali ;
Babich, John W. ;
Kratochwil, Clemens ;
Giesel, Frederik L. ;
Eisenhut, Michael ;
Kopka, Klaus ;
Haberkorn, Uwe .
JOURNAL OF NUCLEAR MEDICINE, 2016, 57 :79S-89S
[4]  
[Anonymous], 2006, DROPPED, V47, P1643
[5]   Linker Modification Strategies To Control the Prostate-Specific Membrane Antigen (PSMA)-Targeting and Pharmacokinetic Properties of DOTA-Conjugated PSMA Inhibitors [J].
Benesova, Martina ;
Bauder-Wuest, Ulrike ;
Schaefer, Martin ;
Klika, Karel D. ;
Mier, Walter ;
Haberkorn, Uwe ;
Kopka, Klaus ;
Eder, Matthias .
JOURNAL OF MEDICINAL CHEMISTRY, 2016, 59 (05) :1761-1775
[6]   2-(3-{1-Carboxy-5-[(6-[18F]Fluoro-Pyridine-3-Carbonyl)-Amino]-Pentyl}-Ureido)-Pentanedioic Acid, [18F]DCFPyL, a PSMA-Based PET Imaging Agent for Prostate Cancer [J].
Chen, Ying ;
Pullambhatla, Mrudula ;
Foss, Catherine A. ;
Byun, Youngjoo ;
Nimmagadda, Sridhar ;
Senthamizhchelvan, Srinivasan ;
Sgouros, George ;
Mease, Ronnie C. ;
Pomper, Martin G. .
CLINICAL CANCER RESEARCH, 2011, 17 (24) :7645-7653
[7]   Biodistribution, Tumor Detection, and Radiation Dosimetry of 18F-DCFBC, a Low-Molecular-Weight Inhibitor of Prostate-Specific Membrane Antigen, in Patients with Metastatic Prostate Cancer [J].
Cho, Steve Y. ;
Gage, Kenneth L. ;
Mease, Ronnie C. ;
Senthamizhchelvan, Srinivasan ;
Holt, Daniel P. ;
Jeffrey-Kwanisai, Akimosa ;
Endres, Christopher J. ;
Dannals, Robert F. ;
Sgouros, George ;
Lodge, Martin ;
Eisenberger, Mario A. ;
Rodriguez, Ronald ;
Carducci, Michael A. ;
Rojas, Camilo ;
Slusher, Barbara S. ;
Kozikowski, Alan P. ;
Pomper, Martin G. .
JOURNAL OF NUCLEAR MEDICINE, 2012, 53 (12) :1883-1891
[8]  
Dodig D, 2017, FREE RADICAL BIO MED, V53, P292
[9]   PSMA as a target for radiolabelled small molecules [J].
Eder, Matthias ;
Eisenhut, Michael ;
Babich, John ;
Haberkorn, Uwe .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 (06) :819-823
[10]   Evaluation of Hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy [J].
Eiber, Matthias ;
Maurer, Tobias ;
Souvatzoglou, Michael ;
Beer, Ambros J. ;
Ruffani, Alexander ;
Haller, Bernhard ;
Graner, Frank-Philipp ;
Kuebler, Hubert ;
Haberhorn, Uwe ;
Eisenhut, Michael ;
Wester, Hans-Juergen ;
Gschwend, Juergen E. ;
Schwaiger, Markus .
JOURNAL OF NUCLEAR MEDICINE, 2015, 56 (05) :668-674